---
title: "Cardiometabolic multimorbidity among Ghanaian clinic patients: clinical, lifestyle and genetic cor"
id: "plos-one-19-cardiometabolic-multimorbidity-and-associated-clinical-lifestyle-and-genetic"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-19-cardiometabolic-multimorbidity-and-associated-clinical-lifestyle-and-genetic"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362848"
published_at: "2026-11-17T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cardiometabolic multimorbidity among Ghanaian clinic patients: clinical, lifestyle and genetic cor
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-19-cardiometabolic-multimorbidity-and-associated-clinical-lifestyle-and-genetic
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362848)
- **Published At:** 2026-11-17T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This hospital-based cross-sectional study enrolled 203 adult clinic attendees in Cape Coast, Ghana, to profile **cardiometabolic multimorbidity** and examine clinical, lifestyle and candidate genetic correlates. - Cardiometabolic multimorbidity was defined as two or more of hypertension, type 2 diabetes, metabolic syndrome (MetS), or chronic kidney disease (CKD). - Over 80% of participants had two or more cardiometabolic conditions; more than two-thirds met criteria for **MetS**, and over 80% were overweight or obese. - Most participants were on treatment: ~90% on antihypertensives and >90% on glucose-lowering therapy, yet uncontrolled blood pressure and hyperglycaemia remained common. - Obesity emerged as the strongest independent predictor of CKD in multivariable models; obese I/II categories showed adjusted odds ratios in the range reported by the authors. - Use of glucose-lowering medication correlated with better glycaemic control (OR reported by authors), while antihypertensive therapy associated with lower odds of uncontrolled BP. - Among genotyped candidates, the **TCF7L2 rs7903146 CT** genotype associated with higher odds of hypertension; most other variants—including **APOL1** risk alleles—showed no consistent associations in this sample. - Predictive models combining clinical, lifestyle and genetic variables had higher in-sample discrimination (AUCs 0.83–0.89) than clinical/lifestyle models (AUCs 0.76–0.83); genetic-only models performed poorly (AUCs 0.63–0.67). - The authors caution that genetic analyses were exploratory, that single-time eGFR without persistence or albuminuria assessment limits CKD classification, and that findings require replication in larger, community-based cohorts.
## Clinical Analysis & Structured Key Points
Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Background Cardiometabolic multimorbidity (coexistence of hypertension, type 2 diabetes, metabolic syndrome and chronic kidney disease) is rising in sub‑Saharan Africa (SSA), but data integrating clinical, lifestyle and genetic determinants in Ghana are limited. This study aimed to characterise the burden of cardiometabolic multimorbidity among Ghanaian clinic attendees and evaluate the associations of clinical, lifestyle, and candidate genetic variants with hypertension, diabetes, metabolic syndrome, and CKD. Methods This cross-sectional study assessed 203 adults attending specialised clinics at a tertiary hospital in Cape Coast, Ghana, between 17 May 2023 and 30 April 2024. Data were collected on participants’ sociodemographic and clinicodemographic characteristics, in addition to lifestyle information obtained through structured questionnaires. Selected candidate variants ( TCF7L2 rs7903146, AGT rs699, ACE rs4343, LEPR rs1137101, ADRB3 rs4994, KCNJ11 rs5219, PPARG rs1801282, APOL1 risk variants) were genotyped. Multivariable logistic regression models were used to evaluate the determinants of blood pressure, elevated glucose levels, metabolic syndrome, and CKD. Receiver operating characteristic analysis compared the predictive performance of clinical/lifestyle, genetic, and combined models. Results Over 80% of participants had ≥ 2 cardiometabolic conditions; > 80% were overweight/obese, and >2/3 met the metabolic syndrome criteria. Despite high treatment rates, uncontrolled BP and hyperglycaemia were common. Obesity was the strongest independent predictor of CKD (aORs:7–8 for Obese I/II). The use of glucose-lowering medication was associated with better glycaemic control (OR: 7.16, 95% CI: 3.31–15.47, p T ( TCF7L2 ) was chosen for its role in glucose metabolism and type 2 diabetes susceptibility; rs699 A>G ( AGT ) and rs4343 G > A ( ACE ) for their involvement in the renin–angiotensin–aldosterone system and blood pressure regulation; rs1137101 A > G ( LEPR ) and rs4994 A > G ( ADRB3 ) for their roles in obesity, energy homeostasis, and metabolic syndrome and APOL1 risk variants (rs73885319, rs60910145, rs71785313) for their established association with chronic kidney disease and cardiovascular risk among individuals of African ancestry. The KCNJ11 rs5219 variant was included because of its involvement in pancreatic β-cell function and insulin secretion, while the PPARG rs1801282 (Pro12Ala) polymorphism was selected due to its role in adipogenesis, lipid metabolism, and insulin sensitivity. These variants have been consistently associated with type 2 diabetes and related metabolic disorders. Genotyping was done using Iplex GOLD SNP genotyping protocol on the Agena MassARRAY® system (Agena Bioscience™, San Diego, CA, USA) and TaqMan genotyping assay kits (assay ID: C__98253221_10 - rs73885319; assay ID: C__89555688_10-rs60910145; assay ID: C_102754756_10-rs71785313). Quality assurance All study personnel were trained on standardised study procedures before data collection. Standard operating procedures (SOPs) were followed throughout the study to ensure consistency. Anthropometric and blood pressure measurements were performed using calibrated equipment. Venous blood samples were collected under aseptic conditions and processed according to laboratory protocols, with internal quality control measures applied during biochemical analyses using the Selectra Pro analyzer. Genomic DNA extraction and genotyping were performed according to the manufacturer’s protocols. DNA quality was assessed using NanoDrop spectrophotometry, and only high-quality samples were included. Positive and negative controls were included during genotyping, and samples with poor quality or ambiguous results were either repeated or excluded according to predefined criteria. Data entries were checked regularly for completeness and consistency prior to analysis. Ethical consideration This study received ethical clearance from the Cape Coast Teaching Hospital Ethical Review Committee (CCTHERC/EC/2023/090 and CCTHERC/EC/2025/076). Written informed consent was obtained from all participants. The study followed Good Clinical Practice guidelines and the Declaration of Helsinki. Data analysis Epicollect 5 was used to gather data for this study [ 21 ]. Data were analysed using Stata version 18 (StataCorp, College Station, TX, USA). Continuous variables were summarised using means and standard deviations, while categorical variables were presented as frequencies and percentages. Normality of continuous variables was assessed prior to analysis. Univariate and multivariable logistic regression analyses examined the associations between genetic and non-genetic factors and four cardiometabolic outcomes: hypertension, diabetes mellitus, MetS, and CKD. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. Analyses were conducted using sequential models: Model 1 was unadjusted for non-genetic factors and Model 2 was adjusted for genetic variables. Candidate variables for multivariable models were selected based on clinical relevance, biological plausibility and their observed associations in the univariate analyses. Categorical variables were entered using clinically appropriate reference categories, as indicated in the regression tables. The number of outcome events was considered in relation to the number of covariates included in each model to minimise overfitting.ROC curve analyses were used to assess and compare the discriminatory performance of the clinical/lifestyle, genetic, and combined models. The reported AUCs represent apparent (in-sample) discrimination, as the models were developed and evaluated using the same study sample without internal or external validation.A p-value <0.05 was considered statistically significant. Given the exploratory nature of the candidate-gene analyses, no formal adjustment for multiple comparisons was applied. Accordingly, p-values from the genetic association analyses are nominal, and observed genetic associations were interpreted cautiously as exploratory findings requiring confirmation in larger independent cohorts. Results Participant characteristics A total of 203 participants were enrolled, of whom 73.9% were female. The study population was predominantly elderly, with most participants aged ≥60 years, and the majority had both diabetes and hypertension. Average age between male (67.77 ± 9.59) and female (62.46 ± 9.47) was statistically significant (p = 0.001). Long-standing disease was common, with most participants reporting a duration of diabetes and hypertension exceeding 10 years. Approximately 90% of participants were receiving antihypertensive medications, while over 90% were on glucose-lowering therapy ( Table 1 ). Overweight and obesity was observed in over 80% of both male and female participants. Just around 25% of participants had a family history
## Related Clinical Research

- [Medicinal Plants and Diabetic Nephropathy: Phytochemicals, Mechanisms, and Therapeutic Potential](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and.md)
- [Self-Management Program Lowers HbA1c, eGFR, SBP, LDL-C in High-Risk DKD Patients with Type 2 Diabe](https://medichelpline.com/clinical-feed/plos-one-11-effectiveness-of-a-self-management-intervention-on-clinical-outcomes-among.md)
- [Single-cell scTWAS identifies immune cell–specific genes linked to gestational diabetes](https://medichelpline.com/clinical-feed/plos-one-0-leveraging-expression-quantitative-trait-loci-information-in-single-cell.md)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.